Singapore: These 5 Drugs Face Patent Expirations and Generic Entry in 2026 - 2027

Generic name: betrixaban
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: November 15, 2027
Generic Entry Controlled by: Singapore Patent 10201504425S

BEVYXXA is a drug marketed by Portola Pharms Inc. There are five patents protecting this drug.

This drug has sixty-seven patent family members in twenty-six countries. There has been litigation on patents covering BEVYXXA

See drug price trends for BEVYXXA.

The generic ingredient in BEVYXXA is betrixaban. Additional details are available on the betrixaban profile page.

Generic name: olaparib
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: October 17, 2026
Generic Entry Controlled by: Singapore Patent 10201408404X

LYNPARZA is a drug marketed by Astrazeneca. There are twelve patents protecting this drug. Three tentatively approved generics are ready to enter the market.

This drug has two hundred and fifty-four patent family members in fifty-two countries. There has been litigation on patents covering LYNPARZA

See drug price trends for LYNPARZA.

The generic ingredient in LYNPARZA is olaparib. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the olaparib profile page.

Generic name: olaparib
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: October 15, 2027
Generic Entry Controlled by: Singapore Patent 168,523

LYNPARZA is a drug marketed by Astrazeneca. There are twelve patents protecting this drug. Three tentatively approved generics are ready to enter the market.

This drug has two hundred and fifty-four patent family members in fifty-two countries. There has been litigation on patents covering LYNPARZA

See drug price trends for LYNPARZA.

The generic ingredient in LYNPARZA is olaparib. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the olaparib profile page.

Generic name: ixazomib citrate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: August 06, 2027
Generic Entry Controlled by: Singapore Patent 10201508712Q

NINLARO is a drug marketed by Takeda Pharms Usa. There are seven patents protecting this drug.

This drug has one hundred and eighty-six patent family members in forty-four countries. There has been litigation on patents covering NINLARO

See drug price trends for NINLARO.

The generic ingredient in NINLARO is ixazomib citrate. One supplier is listed for this generic product. Additional details are available on the ixazomib citrate profile page.

Generic name: exenatide synthetic
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: June 28, 2026
Generic Entry Controlled by: Singapore Patent 10201402181S

BYDUREON is a drug marketed by Astrazeneca Ab. There are eleven patents protecting this drug.

This drug has three hundred and forty-six patent family members in forty-eight countries. There has been litigation on patents covering BYDUREON

See drug price trends for BYDUREON.

The generic ingredient in BYDUREON is exenatide synthetic. There are seven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the exenatide synthetic profile page.

Generic name: exenatide synthetic
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: June 21, 2027
Generic Entry Controlled by: Singapore Patent 172,741

BYDUREON is a drug marketed by Astrazeneca Ab. There are eleven patents protecting this drug.

This drug has three hundred and forty-six patent family members in forty-eight countries. There has been litigation on patents covering BYDUREON

See drug price trends for BYDUREON.

The generic ingredient in BYDUREON is exenatide synthetic. There are seven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the exenatide synthetic profile page.

Generic name: menthol; methyl salicylate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: August 04, 2026
Generic Entry Controlled by: Singapore Patent 174,034

SALONPAS is a drug marketed by Hisamitsu Pharm Co. There are two patents protecting this drug.

This drug has twenty patent family members in sixteen countries.

The generic ingredient in SALONPAS is menthol; methyl salicylate. There are eighteen drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the menthol; methyl salicylate profile page.

Generic name: alcaftadine
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: March 31, 2026
Generic Entry Controlled by: Singapore Patent 170,044

LASTACAFT is a drug marketed by Abbvie. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has forty-six patent family members in thirty countries. There has been litigation on patents covering LASTACAFT

See drug price trends for LASTACAFT.

The generic ingredient in LASTACAFT is alcaftadine. There are six drug master file entries for this API. Four suppliers are listed for this generic product. Additional details are available on the alcaftadine profile page.

Generic name: florbetapir f-18
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: March 26, 2027
Generic Entry Controlled by: Singapore Patent 173,338

AMYVID is a drug marketed by Avid Radiopharms Inc. There are two patents protecting this drug.

This drug has fifty-one patent family members in thirty-three countries. There has been litigation on patents covering AMYVID

The generic ingredient in AMYVID is florbetapir f-18. One supplier is listed for this generic product. Additional details are available on the florbetapir f-18 profile page.

Generic name: ticagrelor
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: August 20, 2027
Generic Entry Controlled by: Singapore Patent 177,162

BRILINTA is a drug marketed by Astrazeneca. There are three patents protecting this drug and two Paragraph IV challenges. One tentatively approved generic is ready to enter the market.

This drug has one hundred and forty-seven patent family members in forty-four countries. There has been litigation on patents covering BRILINTA

See drug price trends for BRILINTA.

The generic ingredient in BRILINTA is ticagrelor. There are twenty-one drug master file entries for this API. Twenty-five suppliers are listed for this generic product. Additional details are available on the ticagrelor profile page.

Generic name: dapagliflozin
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: June 21, 2027
Generic Entry Controlled by: Singapore Patent 10201402181S

FARXIGA is a drug marketed by Astrazeneca Ab. There are nineteen patents protecting this drug and one Paragraph IV challenge. Sixteen tentatively approved generics are ready to enter the market.

This drug has four hundred and fifty-one patent family members in fifty-two countries. There has been litigation on patents covering FARXIGA

See drug price trends for FARXIGA.

The generic ingredient in FARXIGA is dapagliflozin. There are twenty-six drug master file entries for this API. Five suppliers are listed for this generic product. Additional details are available on the dapagliflozin profile page.

Generic name: dapagliflozin
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: June 21, 2027
Generic Entry Controlled by: Singapore Patent 172,741

FARXIGA is a drug marketed by Astrazeneca Ab. There are nineteen patents protecting this drug and one Paragraph IV challenge. Sixteen tentatively approved generics are ready to enter the market.

This drug has four hundred and fifty-one patent family members in fifty-two countries. There has been litigation on patents covering FARXIGA

See drug price trends for FARXIGA.

The generic ingredient in FARXIGA is dapagliflozin. There are twenty-six drug master file entries for this API. Five suppliers are listed for this generic product. Additional details are available on the dapagliflozin profile page.

Generic name: ruxolitinib phosphate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: June 13, 2027
Generic Entry Controlled by: Singapore Patent 10201912675V

JAKAFI is a drug marketed by Incyte Corp. There are eight patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and thirty-six patent family members in forty-six countries. There has been litigation on patents covering JAKAFI

See drug price trends for JAKAFI.

The generic ingredient in JAKAFI is ruxolitinib phosphate. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ruxolitinib phosphate profile page.

Generic name: ruxolitinib phosphate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: June 13, 2027
Generic Entry Controlled by: Singapore Patent 182,198

JAKAFI is a drug marketed by Incyte Corp. There are eight patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and thirty-six patent family members in forty-six countries. There has been litigation on patents covering JAKAFI

See drug price trends for JAKAFI.

The generic ingredient in JAKAFI is ruxolitinib phosphate. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ruxolitinib phosphate profile page.

Generic name: dapagliflozin; saxagliptin hydrochloride
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: June 21, 2027
Generic Entry Controlled by: Singapore Patent 10201402181S

QTERN is a drug marketed by Astrazeneca Ab. There are eight patents protecting this drug and one Paragraph IV challenge.

This drug has three hundred and thirteen patent family members in forty-eight countries. There has been litigation on patents covering QTERN

See drug price trends for QTERN.

The generic ingredient in QTERN is dapagliflozin; saxagliptin hydrochloride. There are twenty-six drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the dapagliflozin; saxagliptin hydrochloride profile page.

Generic name: dapagliflozin; saxagliptin hydrochloride
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: June 21, 2027
Generic Entry Controlled by: Singapore Patent 172,741

QTERN is a drug marketed by Astrazeneca Ab. There are eight patents protecting this drug and one Paragraph IV challenge.

This drug has three hundred and thirteen patent family members in forty-eight countries. There has been litigation on patents covering QTERN

See drug price trends for QTERN.

The generic ingredient in QTERN is dapagliflozin; saxagliptin hydrochloride. There are twenty-six drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the dapagliflozin; saxagliptin hydrochloride profile page.

Generic name: edoxaban tosylate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: March 29, 2027
Generic Entry Controlled by: Singapore Patent 179,497

SAVAYSA is a drug marketed by Daiichi Sankyo Inc. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and one patent family members in thirty-four countries. There has been litigation on patents covering SAVAYSA

See drug price trends for SAVAYSA.

The generic ingredient in SAVAYSA is edoxaban tosylate. There are four drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the edoxaban tosylate profile page.

Generic name: linagliptin
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: April 30, 2027
Generic Entry Controlled by: Singapore Patent 171,649

TRADJENTA is a drug marketed by Boehringer Ingelheim. There are eleven patents protecting this drug and one Paragraph IV challenge. Three tentatively approved generics are ready to enter the market.

This drug has four hundred and eighty-six patent family members in forty-five countries. There has been litigation on patents covering TRADJENTA

See drug price trends for TRADJENTA.

The generic ingredient in TRADJENTA is linagliptin. There are nineteen drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the linagliptin profile page.

Generic name: ruxolitinib phosphate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: June 13, 2027
Generic Entry Controlled by: Singapore Patent 10201912675V

OPZELURA is a drug marketed by Incyte Corp. There are nineteen patents protecting this drug.

This drug has three hundred and thirty-seven patent family members in forty-nine countries. There has been litigation on patents covering OPZELURA

See drug price trends for OPZELURA.

The generic ingredient in OPZELURA is ruxolitinib phosphate. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ruxolitinib phosphate profile page.

Generic name: ruxolitinib phosphate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: June 13, 2027
Generic Entry Controlled by: Singapore Patent 182,198

OPZELURA is a drug marketed by Incyte Corp. There are nineteen patents protecting this drug.

This drug has three hundred and thirty-seven patent family members in forty-nine countries. There has been litigation on patents covering OPZELURA

See drug price trends for OPZELURA.

The generic ingredient in OPZELURA is ruxolitinib phosphate. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ruxolitinib phosphate profile page.

Generic name: ivabradine hydrochloride
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: February 21, 2026
Generic Entry Controlled by: Singapore Patent 125,228

CORLANOR is a drug marketed by Amgen Inc. There are eight patents protecting this drug.

This drug has ninety-seven patent family members in forty-two countries. There has been litigation on patents covering CORLANOR

See drug price trends for CORLANOR.

The generic ingredient in CORLANOR is ivabradine hydrochloride. There are nine drug master file entries for this API. Eleven suppliers are listed for this generic product. Additional details are available on the ivabradine hydrochloride profile page.